Naringenin attenuates NAFLD by reducing the expression levels of NF-κB, NLRP3, IL-1β, and IL-18 in the NF-κB/NLRP3 pathway [68]. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.